Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6.
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Cognitive motor interference in multiple sclerosis: Insights from a systematic, quantitative review.
A new dawn for genetic association studies in multiple sclerosis.
Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease?
Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.
Activation of the niacin receptor HCA reduces demyelination and neurofilament loss, and promotes functional recovery after spinal cord injury in mice.
Epigenetic Modifications in Neurological Diseases: Natural Products as Epigenetic Modulators a Treatment Strategy.
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply.
Circulating immune cells in multiple sclerosis.
Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
Global progress in the control of viral hepatitis and acceptable delay in Hepatitis B immunization.
Transcriptome sequencing of neurologic diseases associated genes in HHV-6A infected human astrocyte.
Progressive multifocal leukoencephalopathy after liver transplantation can have favorable or unfavorable outcome.
[Symptoms of obsessive-compulsive disorder in neurological diseases].
The Added Value of Family Material in the Discovery of Multiple Sclerosis Genes.
Symptomatic Management of Multiple Sclerosis-Associated Tremor Among Participants in the NARCOMS Registry.
Network of nuclear receptor ligands in multiple sclerosis: Common pathways and interactions of sex-steroids, corticosteroids and vitamin D3-derived molecules.
Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment.
Neuromyelitis optica spectrum disorders in children and adolescents.
Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.
In vivo modification of tRNA with an artificial nucleobase leads to full disease remission in an animal model of multiple sclerosis.
Growing Older With a Physical Disability: A Special Application of the Successful Aging Paradigm.
Pages
« first
‹ previous
…
828
829
830
831
832
833
834
835
836
…
next ›
last »